COMMUNIQUÉS West-GlobeNewswire

Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis
14/10/2026
New dose-ranging cohort in FAP builds on compelling early clinical evidence observed with zolucatetide in patients with FAP and concomitant desmoid tumors Zolucatetide directly inhibits β-catenin:TCF, targeting the APC- [...]
Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026
14/10/2026
ALACHUA, Fla. and TAMPA, Fla., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, [...]
Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film
14/10/2026
Differentiated, portable buccal film would offer patients and caregivers an alternative to existing nasal and rectal seizure rescue treatments, a market opportunity that exceeds $450 million annually in the U.S. Patient [...]
Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
14/10/2026
Establishes strategic commercial reach across the Middle East and North Africa, advancing Ocugen’s goal of enabling global patient access to potentially transformational gene therapies Expands access to a potential one- [...]
Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome
14/10/2026
– Company on track to initiate first-ever formal clinical trial in Peeling Skin Syndrome before year end – Orphan Drug designation milestone provides 10 years of market exclusivity for Peeling Skin Syndrome in Europe [...]
Rakovina Therapeutics Secures Exclusivity on Optimized kt-5000 Lead Profile from Variational AI
14/10/2026
Agreement provides Rakovina exclusive access to its optimized kt-5000 target profile and extends AI-powered lead optimization through year-end at no additional cost VANCOUVER, British Columbia, Oct. 14, 2026 (GLOBE [...]
Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg
14/10/2026
AVT29 submitted to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli® (aflibercept 2 mg) High-dose aflibercept offers the potential to reduce treatment frequency for [...]
Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg
14/10/2026
AVT29 submitted to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli ® (aflibercept 2 mg) High-dose aflibercept offers the potential to reduce treatment frequency for [...]
seragy Launches with €12 Million Financing to Advance Quantitative Biomarkers for Neurodegenerative Diseases
14/10/2026
Development of quantitative biomarker strategies for proteopathies through seragy’s proprietary Se RAS ® technology Expansion of the company’s laboratory and analytical capabilities with funding from Commerzbank, the [...]
Engitix appoints Ryan Richardson to Board of Directors as company advances towards clinical development
14/10/2026
LONDON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Engitix Ltd., a biotechnology company pioneering extracellular matrix (ECM)-based drug discovery and development in oncology, fibrosis and fibro-inflammatory diseases, today [...]
Nxera Pharma Enters into Exclusive License, Supply and Commercialization Agreement with Synmosa for QUVIVIQ® (daridorexant) Across Eight Asia-Pacific Markets
14/10/2026
Synmosa to lead regulatory approvals, market access, distribution and sales in Singapore, Thailand, Indonesia, Malaysia, the Philippines, Vietnam, Australia and New Zealand. Nxera to supply drug product and receive an [...]
Sapreme Therapeutics announces oral presentation of new preclinical data on lead Duchenne muscular dystrophy candidate SPM-2551 at OTS 2026
14/10/2026
SPM-2551 demonstrated robust and durable pharmacological activity following a single low-dose administration in preclinical Duchenne muscular dystrophy (DMD) models Data support Sapreme's proprietary SPT platform, [...]
Orion publishes Interim Report for January–September 2026 and holds a webcast on 28 October 2026
14/10/2026
ORION CORPORATION PRESS RELEASE 14 OCTOBER 2026 at 9.00 EEST Orion publishes Interim Report for January–September 2026 and holds a webcast on 28 October 2026 Orion will publish Interim Report for January–September 2026 [...]
Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026
14/10/2026
First clinical data for leniolisib in a larger group of PID participants beyond APDS, supporting the potential of targeted PI3Kδ inhibition to address immune dysregulation Leniolisib was well-tolerated, with benefits [...]
Phonak launches Roger On Sphere™: the first AI-powered remote microphone to separate speech from noise in real time
14/10/2026
STÄFA, Switzerland, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Phonak today announced Roger On Sphere™, the world's first remote microphone powered by a deep neural network (DNN) that separates speech from background noise in [...]
Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity
14/10/2026
-- Launch follows MHLW approval of IMCIVREE for acquired hypothalamic obesity and inclusion on Japan's National Health Insurance drug price list -- -- IMCIVREE is the first approved therapy in Japan for patients living [...]
Orum Therapeutics Doses First Patient in Phase 1 Trial of ORM-1153, a CD123-GSPT1 Degrader-Antibody Conjugate
14/10/2026
BOSTON and DAEJEON, South Korea, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Orum Therapeutics (“Orum” or the “Company”) (KRX: 475830), a biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today [...]
TRexBio Announces Closing of Initial Public Offering
13/10/2026
SOUTH SAN FRANCISCO, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- TRex Bio, Inc. (“TRexBio”) (Nasdaq: TRXB), a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of [...]
Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
13/10/2026
Press release – No. 20 / 2026 Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases Collaboration will combine [...]

Pages